CT News and Research

RSS

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Breast cancer continues to be a dynamic field of research, and the CTRC-AACR San Antonio Breast Cancer Symposium, now in its 32nd year, is the premier destination to present new data on emerging therapies.

14 Dec 2009

Researchers present new data for diagnosis and management of beast cancer

As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions.

14 Dec 2009

New antibody-drug compound halts growth of metastatic breast tumors

A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.

14 Dec 2009

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.

11 Dec 2009

Drop in U.S. colorectal cancer deaths

The American Society for Gastrointestinal Endoscopy (ASGE) lauds the recent news of the decline in U.S. colorectal cancer death and incidence rates. The report, released this week, shows that from 1975 to 2000, incidence rates dropped 22 percent and death rates dropped 26 percent.

10 Dec 2009

Enzo Biochem and Ikonisys sign agreement to market molecular-based cervical cancer test

Enzo Biochem, Inc. announced today that its Enzo Clinical Lab division has entered into an exclusive marketing partnership covering the States of New York and New Jersey with privately-owned Ikonisys, Inc., of New Haven, CT, relating to Ikonisys’ proprietary oncoFISH® cervical test, a laboratory developed test for cervical cancer prevention.

10 Dec 2009

Biomoda, Christiana Care Health System partner in study of CyPath lung cancer diagnostic test

Cancer diagnostics company Biomoda, Inc. today announced that The Helen F. Graham Cancer Center associated with Christiana Care Health System, a screening site for the International Early Lung Cancer Program (I-ELCAP), will recruit a cohort of patients diagnosed with lung cancer to participate in the final stage of the Phase II pilot study of the investigational CyPath® assay, an early-stage diagnostic test for lung cancer.

10 Dec 2009

Roche launches new automated clinical laboratory system for HPV and CT/NG tests

Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.

10 Dec 2009

Insurrecta Nex: Will Catholic Bishops truly defend babies?

Beginning Wednesday, December 9, Insurrecta Nex team members will travel to 13 Cathedrals in 9 states to hold vigils and press conferences. The tour will finish at the Boston Cathedral, the seat of Cardinal O'Malley, the site of decades of scandal with the Kennedy and the Kerry families.

9 Dec 2009

New GE LightSpeed VCT scanner reduces radiation exposure by half

The Methodist Hospital System became the first in Houston this month to use new technology that dramatically reduces CT radiation doses without compromising the quality of the image.

9 Dec 2009

Veran Medical Technologies' SPiN Drive System receives FDA marketing clearance

Veran Medical Technologies announced today that it received clearance (K091934) from the U.S. Food and Drug Administration (FDA) to market a product for the delivery of instruments through the pulmonary tract. "Veran is excited about this clearance as it allows the company to address a huge unmet clinical need in lung cancer diagnosis and treatment," said Jerome R. Edwards, Veran president and chief executive officer.

8 Dec 2009

FDA probes excessive radiation dose cases

The Associated Press/Wall Street Journal: "Federal health regulators are investigating reports of dangerous radiation levels at two more California hospitals, following earlier unsafe medical scans at a Los Angeles facility. The Food and Drug Administration is probing the use of CT scans at Glendale Adventist Medical Center and Providence St. Joseph Medical Center in Burbank, Calif. The brain scans are used to diagnose strokes.

8 Dec 2009

Excess radiation exposure during CT perfusion imaging: FDA issues interim recommendations

As part of an ongoing investigation into cases of excess radiation during CT perfusion imaging of the brain, the U.S. Food and Drug Administration today provided imaging facilities and practitioners with interim recommendations to help prevent additional problems.

8 Dec 2009

Defibrotide drug effective against hepatic veno-occlusive disease

Defibrotide, a novel drug which modulates the response of blood vessels to injury, was markedly more effective than standard treatment in post-stem cell transplant patients with hepatic veno-occlusive disease, a life threatening toxicity of transplant caused by blockages in tiny blood vessels of the liver, according to a study led by Dana-Farber Cancer Institute scientists.

8 Dec 2009

H1N1 virus produces pulmonary damage similar to earlier flu pandemics

In fatal cases of 2009 H1N1 influenza, the virus can damage cells throughout the respiratory airway, much like the viruses that caused the 1918 and 1957 influenza pandemics, report researchers from the National Institutes of Health (NIH) and the New York City Office of Chief Medical Examiner.

8 Dec 2009

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Monday, Dec. 7 (Ernest N. Morial Convention Center, Room 343-345, 5:15 pm CT).

8 Dec 2009

BD Diagnostics receives FDA clearance on Amplified DNA Assays

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) Chlamydia trachomatis (CT) Qx and BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.

From BD (Becton, Dickinson and Company) 8 Dec 2009

New PenLink connectivity package installed at Zwanger-Pesiri Radiology

The Medipattern Corporation, a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, and PenRad Technologies, Inc., a leader in the development of mammography information systems (MIS) are pleased to announce the first installation of the new PenLink connectivity package at Zwanger-Pesiri Radiology, Long Island's largest private medical imaging practice.

7 Dec 2009

New three-drug combination may be effective for treating patients with bone cancer

A new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.

7 Dec 2009

Bortezomib can improve control of GVHD and immune system recovery

A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology's (ASH) annual meeting on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial Convention Center, Room 243-245, 5:45 pm CT).

6 Dec 2009

CT News and Research

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Researchers present new data for diagnosis and management of beast cancer

New antibody-drug compound halts growth of metastatic breast tumors

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Drop in U.S. colorectal cancer deaths

Enzo Biochem and Ikonisys sign agreement to market molecular-based cervical cancer test

Biomoda, Christiana Care Health System partner in study of CyPath lung cancer diagnostic test

Roche launches new automated clinical laboratory system for HPV and CT/NG tests

Insurrecta Nex: Will Catholic Bishops truly defend babies?

New GE LightSpeed VCT scanner reduces radiation exposure by half

Veran Medical Technologies' SPiN Drive System receives FDA marketing clearance

FDA probes excessive radiation dose cases

Excess radiation exposure during CT perfusion imaging: FDA issues interim recommendations

Defibrotide drug effective against hepatic veno-occlusive disease

H1N1 virus produces pulmonary damage similar to earlier flu pandemics

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

BD Diagnostics receives FDA clearance on Amplified DNA Assays

New PenLink connectivity package installed at Zwanger-Pesiri Radiology

New three-drug combination may be effective for treating patients with bone cancer

Bortezomib can improve control of GVHD and immune system recovery

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News